Clinical Trial Finder

Inclusion Criteria:

• - Adult patients (> 18 years old) with a diagnosis of thumb CMC OA.

• - Diagnosis of thumb CMC OA.

• - History, clinical exam, and radiographic findings, as done in prior studies on this topic.

• - Subjective: thumb or wrist pain at rest or with activity, joint stiffness.

• - Exam: basal joint tenderness, decreased mobility, deformity, instability.

• - Radiograph: joint space narrowing, subchondral sclerosis, osteophytes, subchondral cysts, Eaton-Littler stage.

• - Failed conservative management with oral pain medication and splinting for at least 3 months.

Exclusion Criteria:

• - Severe osteoarthritis (Eaton-Littler stage 4) or too large osteophytes to allow for injection into the joint space Inflammatory arthritis.

• - Any concomitant hand conditions (i.e. carpal tunnel, trigger finger, etc) - Prior significant hand trauma related to the thumb or first CMC joint.

• - Prior intervention or hand surgery.

• - Patients with fibromyalgia or complex regional pain syndrome (CRPS) - Pregnant and breastfeeding patients will also be excluded.

We also will exclude individuals attempting to conceive or who could become pregnant within 6-months of treatment.

Thumb carpometacarpal (CMC) osteoarthritis (OA) is one of the most common conditions treated by hand surgeons in the US. The treatment algorithm includes a stepwise strategy starting with conservative management and escalating to operative interventions when nonoperative measures fail to control pain or there is progression to a painful joint. Intra-articular injection of steroids represents a mainstay in the treatment approach for patients with thumb CMC OA, but despite its ubiquity, the American College of Rheumatology only conditionally recommends steroid injections due to a lack of evidence. Additionally, steroid injections carry significant risks, including the possibility of tissue atrophy, skin hypopigmentation, and joint arthropathy. As a result, alternative means have been sought to better treat pain and potentially delay the need for surgery. Botulinum toxin (BoNT) may be one such alternative. BoNT is produced by Clostridium botulinum and exerts temporary neuromodulation by rapidly and strongly binding to presynaptic cholinergic nerve terminals. BoNT has also been shown to inhibit the secretion of pain mediators from the nerve endings of the dorsal root ganglia, reduce local inflammation around nerve endings, deactivate sodium channels, and perform retrograde axonal transport. Due to the growing evidence of efficacy in treating neuropathic pain, the use of BoNT has become incorporated in the management of chronic migraines, trigeminal neuralgia, spinal cord injuries, and post-stroke pain syndrome. Additionally, intra-articular BoNT injections were shown to decrease pain in patients with knee and shoulder refractory arthritis. The investigators propose that intra-articular BoNT injections may decrease pain in patients with thumb CMC OA through the chemical denervation of articular pain fibers.

Arms

Active Comparator: Control

Patients in this group will receive standard-of-care corticosteroid injections.

Experimental: Botulinum Toxin

Patients in this group will receive a Botulinum Toxin injection.

Interventions

Drug: - Botulinum toxin

Patients in this group will receive an injection of Botulinum toxin.

Drug: - Standard-of-care corticosteroid injections

Patients in this group will receive an injection of corticosteroid injections, which are considered standard of care.